PRESS RELEASES

 

 

ABOLOGIX awarded a 2 year Innosuisse Innovation project in collaboration with the University of Geneva Hospitals

Geneva, Switzerland, July 24, 2020 – The joint project will allow the company to further characterize the effect of blocking JAM-C (Junction Adhesion Molecule C) in hematological malignancies.



ABOLOGIX is one of the winners in Stage I of the Venture Kick competition

Geneva, Switzerland, June 10, 2020 – Abologix will receive funding from Venture Kick in order to advance its business development activities and its fundraising efforts.

 


ABOLOGIX selected as one of the top 50 start ups in french-speaking Switzerland

Geneva, Switzerland, December 18, 2019 – Abologix is profiled in the leading swiss Business magazine “Bilan” as one of the most promissing start ups in Suisse Romande. The company has been invited to present its investment case in a future event sponsored by “Bilan” to be held in Lausanne, Switzerland.


 

ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

Geneva, Switzerland, July 24, 2019 – Recombinant monoclonal antibody rH225, a blocker of JAM-C (Junction Adhesion Molecule C) generates impressive efficacy data in a Mantle Cell Lymphoma animal model.


 

ABOLOGIX is admitted to Fondation Eclosion, the Geneva life sciences incubator

Geneva, Switzerland, September 5, 2018 – Abologix has been selected to participate in the incubation program sponsored by Fondation Eclosion. As part of this program Abologix will receive business, scientific and financial support from Fondation Eclosion.



ABOLOGIX signs a license agreement with Research Development Foundation

for two monoclonal antibodies for oncology

Geneva, Switzerland, July 19, 2018 – Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.



ABOLOGIX founded in Geneva, Switzerland

Geneva, Switzerland, January 25, 2018 – Abologix, a privately held swiss biotechnology company developing novel immuno-oncology products for the benefit of cancer patients has been founded in Geneva, Switzerland by Dr. Ignacio Faus, Prof. Beat Imhof (University of Geneva) and Prof. Thomas Matthes (Hôpitaux   Universitaires de Genève). 

Copyright © 2020 ABOLOGIX